ERBB2 and neoplasm: The primary treatment of ER positive primary and advanced breast cancer is the non-steroidal anti-estrogen tamoxifen, while HER-2/neu positive tumor treatment is focused on trastuzumab, a monoclonal antibody against the HER-2 receptor.